NCT03836352: Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors

NCT03836352
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: MSI-H, Survivin
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 2
Drug Category: Chemotherapy, Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have tumors that express MSI-H to be eligible
Exclusions: Patients with active CNS metastases and/or carcinomatous meningitis; Patients with prior receipt of survivin-based vaccine(s) and/or immunotherapies
https://ClinicalTrials.gov/show/NCT03836352

Comments are closed.

Up ↑